Centessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 12-Month High – What’s Next?

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA)’s share price reached a new 52-week high during trading on Monday . The stock traded as high as $29.42 and last traded at $28.9640, with a volume of 531929 shares changing hands. The stock had previously closed at $27.98.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Wells Fargo & Company raised their target price on Centessa Pharmaceuticals from $30.00 to $35.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Stephens began coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, October 28th. They issued an “overweight” rating and a $35.00 price objective for the company. Chardan Capital upgraded shares of Centessa Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, November 19th. Lifesci Capital upgraded shares of Centessa Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, September 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $34.78.

Centessa Pharmaceuticals Stock Performance

The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36. The stock’s 50-day moving average price is $24.13 and its 200-day moving average price is $18.32. The company has a market capitalization of $3.90 billion, a P/E ratio of -15.84 and a beta of 1.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.02). As a group, equities analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current year.

Insider Buying and Selling

In other news, CTO Tia L. Bush sold 40,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $26.00, for a total value of $1,040,000.00. Following the transaction, the chief technology officer owned 121,503 shares of the company’s stock, valued at $3,159,078. The trade was a 24.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $22.41, for a total transaction of $134,460.00. Following the completion of the sale, the general counsel owned 105,386 shares in the company, valued at $2,361,700.26. The trade was a 5.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 179,964 shares of company stock valued at $4,106,481 over the last 90 days. 7.09% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. Campbell & CO Investment Adviser LLC bought a new stake in shares of Centessa Pharmaceuticals in the 2nd quarter valued at approximately $218,000. Cutter Capital Management LP lifted its stake in Centessa Pharmaceuticals by 184.3% in the first quarter. Cutter Capital Management LP now owns 418,127 shares of the company’s stock valued at $6,013,000 after acquiring an additional 271,051 shares during the last quarter. American Century Companies Inc. grew its position in Centessa Pharmaceuticals by 1.2% in the first quarter. American Century Companies Inc. now owns 1,092,754 shares of the company’s stock worth $15,714,000 after acquiring an additional 13,046 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Centessa Pharmaceuticals by 20.6% during the 1st quarter. Wellington Management Group LLP now owns 138,767 shares of the company’s stock worth $1,995,000 after purchasing an additional 23,660 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in shares of Centessa Pharmaceuticals during the 1st quarter worth $3,273,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.